HOME >> MEDICINE >> NEWS
Success of experimental herpes vaccine builds momentum for human clinical trials

BOSTON, MA-(Dec. 14, 2004)-A new study provides evidence that a herpes vaccine developed by a Harvard Medical School researcher is a strong candidate for testing in humans. The study, published online Dec. 14 in the Journal of Virology, compared three different experimental vaccines for herpes simplex virus 2 (HSV-2), the virus that causes most cases of genital herpes.

HSV-2 infects one in five Americans, and its prevalence has reached 50 percent in some developing countries, where it also seems to be helping to fuel the spread of HIV. HSV-2 infection, though incurable, typically does not cause major health problems, but can be life-threatening in immunocompromised people and newborn babies infected by their mothers.

Lead author Stephen E. Straus, MD, senior investigator in the Medical Virology Section in the Laboratory of Clinical Infectious Diseases at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, tested the vaccines in two established animal models of herpes infection. The HMS vaccine, developed by David Knipe, HMS professor of microbiology and molecular genetics, called dl5-29, outperformed the other two vaccines, one of which has already been tested in humans.

Straus said that the results argue strongly for taking dl5-29 into human trials. "Based upon d15-29's biological and immunological properties, it appears to be the most compelling new vaccine candidate for genital herpes," he said.

Straus said that dl5-29 seemed especially promising because it solves a critical problem that is believed to underlie the failure of previous candidate vaccines. The dominant approach to herpes vaccine development over the past 20 years has been the delivery of one or two pure glycoproteins found in the outer envelope of the virus in order to induce an antibody response. But in trials of HSV-2 vaccines, a healthy antibody response has not seemed sufficient to protect against infection. One ver
'"/>

Contact: John Lacey
public_affairs@hms.harvard.edu
617-432-0442
Harvard Medical School
14-Dec-2004


Page: 1 2 3

Related medicine news :

1. Success of liver transplantation may be most influenced by three risk factors
2. Success of new treatment halts international blood pressure drug trial
3. Successful therapy for head and neck cancer may lead to long-term circulatory problems
4. Success of nicotine patches linked to genetic make-up
5. Successful, rapid protein crystallization possible with technique developed by UCSD researcher
6. Successful prostate surgery: Its quality of surgery not quantity that matters most
7. Successful implementation of pilot study for HIV antiretroviral therapy in Uganda
8. Successful measles vaccination feasible in low-income countries
9. Scientists analyze stroke studies from the past 50 years; Success rate of experimental drugs described as remarkably dismal
10. Success of plasma centers could hurt Red Cross, study finds
11. New Procedure Makes A Successful Transplant Possible

Post Your Comments:
(Date:5/18/2013)... May 18, 2013 Show And Go Training, ... various different training systems that is all about is getting ... the attention of http://ShowAndGoTrainingReview.com ’s Stan Stevenson, prompting ... is a unique “four phase system” designed to make you ... of time spent working out in the gym. The training ...
(Date:5/18/2013)... Angeles, Ca (PRWEB) May 18, 2013 Losing ... of people. But among the horde of new weight loss ... one most talked about. Recent studies about this newest weight ... achieve one’s ideal body shape. , Garcinia Cambogia is a ... like a tamarind. Eating the fruit can suppress a person’s ...
(Date:5/18/2013)... 18, 2013 John Ravera, D.D.S., a ... of a new member to his dental team, Courtney Marino. ... the field for over 10 years. She received her degree ... was elected a member of Sigma Pi Alpha, a national ... enjoys working with patients of all ages, helping them understand ...
(Date:5/18/2013)... Provo, UT (PRWEB) May 18, 2013 Medical ... pre-launch orders for its much anticipated mobility aid with its ... to create a hands-free crutch alternative that injured ... a broken ankle, for example, can remain active and walk ... team is using its reservation system to ensure those who ...
(Date:5/17/2013)... Salt Lake City, Utah (PRWEB) May 17, 2013 ... muscle by providing their corporate wellness programs to ... system. This has been achieved through rigorous ... into a greater capacity for employee interactions via ... specializes in helping businesses lower employee healthcare ...
Breaking Medicine News(10 mins):Health News:Show And Go Training: Review Examining Eric Cressy's Workout Program Revealed 2Health News:Lose Weight Without Dieting or Exercising with Garcinia Cambogia Select Now Available At HealthCareSupplementz.com 2Health News:Newport Beach Cosmetic Dentist John Ravera Adds New Member to Dental Team 2Health News:FlexLeg Begins Offering New Mobility Aid 2Health News:New Telecommunications Upgrade Provides More Capacity for National Corporate Wellness Programs offered by Orriant 2
(Date:5/17/2013)... 2013  Sorrento Therapeutics, Inc. (OTCBB: SRNE; or ... Small Business Technology Transfer Research (STTR) grant (#1R42AI098182-02) ... Diseases (NIAID), a division of the National Institutes ... human antibody therapeutics to combat Staphylococcus aureus ... including methicillin-resistant S. aureus (MRSA), was ...
(Date:5/17/2013)... 17, 2013  Sony Biotechnology Inc. ("Sony") today announced the ... and 130um sorting chip.  Sony will also be exhibiting its ... SH800 Cell Sorter, the EC800 flow cytometer, and new SP6800 ... 2013, which will be held at the San ... California , from May 20 - 22.  ...
(Date:5/17/2013)... , May 17, 2013  TechAtlas Group ... for their competitive landscape map for the Chronic ... over 90 international companies with drugs and devices ... CKD and its sequelae. (Logo:  ... , hypertension - renal denervation ...
Breaking Medicine Technology:Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4Sony Delivers New Technology for Science to CYTO 2013 2TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2
Cached News: